Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Endocrinología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
ClinicalTrials.gov
A Multinational Observational Study Assessing Insulin Use: Understanding the Challenges Associated With Progression of Therapy - The MOSAIc Type 2 Diabetes Study
OBSERVATIONAL
Inicio: 1 de jul de 2011
ID: NCT01400971
Completado
Fase 4
ClinicalTrials.gov
Practical Implementation of ADA/EASD Consensus Algorithm in Patients With Type 2 Diabetes: Timely Insulin Initiation and Titration
INTERVENTIONAL
Inicio: 1 de may de 2010
ID: NCT01127269
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
INTERVENTIONAL
Inicio: 20 de nov de 2018
ID: NCT03730662
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone
INTERVENTIONAL
Inicio: 1 de abr de 2006
ID: NCT00313313
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
INTERVENTIONAL
Inicio: 2 de may de 2019
ID: NCT03834506
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 10 de ago de 2016
ID: NCT02863328
Completado
Fase 3
ClinicalTrials.gov
The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)
INTERVENTIONAL
Inicio: 22 de jul de 2011
ID: NCT01394952
Aún no recluta
Fase 2
ClinicalTrials.gov
Adrenaline in Early Sepsis Resuscitation in Children- A Randomised Controlled Pilot Study in the Emergency Department (ANDES CHILD)
INTERVENTIONAL
Inicio: 1 de jul de 2024
ID: NCT06478797
Completado
Fase 4
ClinicalTrials.gov
Prospective, Randomized, Open-label, Blinded Endpoint, Forced Titration Study to Compare Telmisartan Combined With HCTZ (80mg/12.5mg), to Valsartan Combined With HCTZ (160mg/12.5mg), for the Control of Mild-to-moderate Hypertension in Obese Patients With Type 2 Diabetes Mellitus Using ABPM.
INTERVENTIONAL
Inicio: 1 de ene de 2003
ID: NCT00239538
Desconocido
Fase 4
ClinicalTrials.gov
Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients
INTERVENTIONAL
Inicio: 1 de sept de 2014
ID: NCT02280174
Completado
ClinicalTrials.gov
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00428220
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
INTERVENTIONAL
Inicio: 1 de may de 2006
ID: NCT00327015
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
INTERVENTIONAL
Inicio: 24 de may de 2024
ID: NCT06419374
Completado
Fase 3
ClinicalTrials.gov
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de may de 2006
ID: NCT00318461
Completado
Fase 4
ClinicalTrials.gov
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de may de 2010
ID: NCT01107886
Completado
Fase 3
ClinicalTrials.gov
A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)
INTERVENTIONAL
Inicio: 1 de feb de 2010
ID: NCT01042769
Activo, no recluta
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
INTERVENTIONAL
Inicio: 1 de nov de 2022
ID: NCT05567796
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00754988
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis
INTERVENTIONAL
Inicio: 7 de nov de 2024
ID: NCT06632457
Completado
Fase 2
ClinicalTrials.gov
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity
INTERVENTIONAL
Inicio: 1 de abr de 2024
ID: NCT06131372
Anterior
1
...
26
27
28
...
434
Siguiente
Filtros